 |
|
Treatment of an Ulcerated Hemangioma With Recombinant Platelet-Derived Growth Factor
Jeffrey L. Sugarman, MD, PhD;
Theodora M. Mauro, MD;
Ilona J. Frieden, MD
From the Department of Dermatology, University of California, San Francisco.
Arch Dermatol. 2002;138:314-316.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
REPORT OF A CASE
We report a case of a 7-month-old girl with a large facial hemangioma
whose ulceration was successfully treated with 0.01% becaplermin (Regranex
[Ortho-McNeil Pharmaceutical, Raritan, NJ], recombinant human platelet-derived
growth factor-BB) gel. She was noted to have a hemangioma precursor on her
face and a heart murmur at the time of birth. After further evaluation, she
was found to have a type 1 interrupted aortic arch, ventricular septic defect,
and patent ductus arteriosis, and she subsequently underwent surgery to correct
her cardiac anomalies. These associated abnormalities are part of PHACE syndrome:
the association of posterior fossa brain malformations, hemangiomas, arterial
anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities.1
Her hemangioma continued to grow rapidly, progressively obstructing
the vision in her right eye, and at age 3 months she was started on oral corticosteroid
therapy . . . [Full Text of this Article]
THERAPEUTIC CHALLENGE
SOLUTION
COMMENT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Hemangiomas of Infancy: Treatment of Ulceration in the Head and Neck
Thomas et al.
Arch Facial Plast Surg 2005;7:312-315.
ABSTRACT
| FULL TEXT
Response of Ulcerated Perineal Hemangiomas of Infancy to Becaplermin Gel, a Recombinant Human Platelet-Derived Growth Factor
Metz et al.
Arch Dermatol 2004;140:867-870.
ABSTRACT
| FULL TEXT
|
